COMPANY WORKBOOK · GILD
Gilead Sciences, Inc.
Healthcare & Life Sciences · Drug Manufacturers - General
$150.56+0.30%
60/100
INTERACTIVE PRICE CHART
Trend and moving averages
RELATIVE PERFORMANCE
GILD versus SPY and SMH
Indexed to 100
Cross-sectional ranking
Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.
Healthcare & Life Sciences
This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.
MODEL READ
Overall score: 60.4. Last ranked 2026-09-22.
QUARTERLY FUNDAMENTALS
Revenue and earnings power
TRAILING P/EN/A
PRICE / SALES6.22
EV / EBITDA14.42
BOOK VALUEN/A
GROSS MARGIN79.6%
PROFIT MARGIN-10.6%
RETURN ON EQUITY-20.7%
FREE CASH FLOW9.77B
What it does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
PRIMARY SOURCES